Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (185)	2/12/1998 6:11:00 PM
From: John S. Sturges	Read Replies (1) \| Respond to of 496

PDLI presents data which we believe will revolutionize organ transplantation. Their drug Zenapax, is in trials head to head with Cyclosporin(the only drug for preventing organ transplant rejection since 1983) and we anticipate that the data will clearly indicate that Zenapax is superior to Cyclosporin. There has been quite a turf war with analysts. M.Geller with CIBC Oppenheimer pro-PDLI and existing biotech underwriters anti-PDLI. I believe Geller's work will be recognized thru PDLI's success and then the market will examine and bid up his best recommendations. GLFD is one of his strong buys and his most undervalued issue with a 12mo. target of $39shr. In short a "Geller Rally". Best regards, John